RVPH - Reviva stock rises ~10% as lung disease drug brilaroxazine shows promise in rat model

2023-05-25 06:46:44 ET

• Reviva Pharmaceuticals ( NASDAQ: RVPH ) presented preclinical data on brilaroxazine in rat model of idiopathic pulmonary fibrosis (IPF) at the 2023 American Thoracic Society (ATS) International Conference.
• IPF is a serious condition in which the lungs become scarred and breathing becomes difficult.
• The company said brilaroxazine showed efficacy with significant improvements in key goals in the bleomycin (BLM)-induced rat model of IPF.
• The BLM-induced rat model received either brilaroxazine 15 mg twice daily for 21 days starting at day 1 (BT) or at day 10 (BI).
• Statistically significant improvements with brilaroxazine versus BLM group include: Prolonged survival — 90% for BT and 89.5% for BI verus 62% survival rate.
• The drug also showed improved lung function, anti-fibrotic and anti-inflammatory effects.
• "This preclinical evaluation in IPF provides proof-of-concept support for the potential of brilaroxazine to treat pulmonary fibrosis and inflammation stemming from underlying dysfunction in serotonin signaling in the lung," said Reviva's Founder, President, and CEO Laxminarayan Bhat.
• RVPH +11.39% to $7.14 premarket May 25

For further details see: